

Serial No. 09/980,516

Response After Final

Amendments to the Claims:

1. (Previously Presented) A formulation which comprises a ligand capable of binding to a HLA-DR protein, said ligand being coupled to a lipid-comprising vesicle.
2. (Previously Presented) The formulation according to claim 1 wherein said lipid-comprising vesicle is a liposome.
3. (Previously Presented) The formulation according to claim 2 wherein said liposome comprises a mixture of diacylphosphatidylcholine and diacylphosphatidylglycerol in a molar ratio ranging between 10:1 and 1:1, wherein the acyl chains are either saturated or unsaturated and have between 14 and 18 carbon atoms in length.
4. (Previously Presented) The formulation according to claim 3, wherein said liposome comprises a polyethyleneglycol derivative of diacylphosphatidylethanolamine.
5. (Previously Presented) The formulation according to claim 4, wherein the polyethyleneglycol has a molecular weight between about 500 and 5000 daltons.
6. (Previously Presented) The formulation according to claim 3, wherein the molar ratio is 10:3.
7. (Previously Presented) The formulation according to claim 4, wherein said liposome comprises a mixture of diacylphosphatidylcholine: diacylphosphatidylglycerol: diacylphosphatidylethanol-amine-polyethyleneglycol in a molar ratio of 10:3:0.1-3.
8. (Previously Presented) The formulation according to claim 2, wherein said liposome comprises a mixture of dipalmitoylphosphatidylcholine:dipalmitoylphosphatidylglycerol in a molar ratio of 10:3 or distearoylphosphatidylcholine:distearoylphosphatidylglycerol in a molar ratio of 10:3.

*Serial No. 09/980,516**Response After Final*

9. (Previously Presented) The formulation according to claim 2, wherein said liposome comprises a mixture of dipalmitoylphosphatidylcholine:dipalmitoylphosphatidylglycerol: dipalmitoylphosphatidylethanolamine-polyethyleneglycol in a molar ratio of 10:3:0.33 or dipalmitoylphosphatidylcholine: dipalmitoylphosphatidylglycerol: distearoylphosphatidylethanolamine-polyethyleneglycol in a molar ratio of 10:3:0.83.

10. (Currently Amended) The formulation according to claim 1, further comprising an additional ligand to one or more proteins selected from a histocompatibility complex protein ~~other than HLA-DR~~, a membrane ATPase, thy-1, an interleukin receptor, annexin II, CD3 (T3), CD4 (T4), CD5 (Ti), CD6 (T12), CD8 (T8), CD11a (LFA-1), CD11b (Mac-1), CD11c (gp150,95), CD1 (Lewis X), CD18, CD19, CD25 (Tac), CD30 (Ki-1), CD43 (leukosialin, sialophorin), CD44 (Pgp-1), CD48 (Blast-1), CD54 (ICAM-1), CD55 (DAF), CD59 (protectin, Mac inhibitor), CD63, CD71 (transferrin receptor), CDw108(GR2), cyclophilin A, cytoskeletal proteins and β 2-microglobulin.

11. (Previously Presented) The formulation according to claim 1, wherein said ligand is an antibody molecule selected from a whole antibody and an antibody fragment.

12. (Previously Presented) The formulation according to claim 1, which comprises a drug effective against a disease or against the symptoms of a disease caused by an infectious agent.

13. (Previously Presented) The formulation according to claim 1, wherein said HLA-DR protein is expressed in a lymphoid cell or a cell of the reticuloendothelial system.

14. (Previously Presented) The formulation according to claim 12, wherein said HLA-DR protein is expressed in a lymphoid cell or a cell of the reticuloendothelial system.

15. (Currently Amended) The formulation according to claim 13, wherein said HLA-DR protein is expressed ~~in~~ in-acquired by HIV.

*Serial No. 09/980,516**Response After Final*

16. (Currently Amended) The formulation according to claim 14, wherein said HLA-DR protein is ~~expressed in~~ acquired by HIV.

17. (Previously Presented) The formulation according to claim 13, wherein said ligand further comprises an additional ligand to one or more of CD4, MHC-I and CD54 proteins.

18. (Previously Presented) The formulation according to claim 14, further comprising an additional ligand to one or more of CD4, MHC-I and CD54 proteins.

19. (Previously Presented) The formulation according to claim 12, wherein said drug is selected from AZT, ddI, ddC, 3TC, indinavir, saquinavir, ritonavir, nelfinavir, ganciclovir, foscarnet, ribavirin, amphotericin B and nystatin A.

20. (Previously Presented) The formulation according to claim 1, wherein said ligand is an anti-Fab' antibody fragment directed against a HLA-DR protein.

21 - 23. (Canceled)